Avanos Medical, Inc. · NYSE:AVNS
Avanos Medical — J.P. Morgan Healthcare Conference 2022
12 slides from Avanos Medical's conference presentation, Jan 11, 2022
Slide 1: J.P. Morgan Healthcare Conference
1 J.P. MORGAN HEALTHCARE CONFERENCE JOE WOODY CHIEF EXECUTIVE OFFICER JANUARY 11, 2022
Slide 2: Forward-Looking Information / Non-GAAP Financial Measures
2 FORWARD-LOOKING INFORMATION NON-GAAP FINANCIAL MEASURES Certain matters in this presentation and webcast, including expectations and planning assumptions and any estimates, projections, and statements relating to our business plans, objectives, acquisitions and transformation initiatives, constitu
Slide 3: Who We Are
3 WHO WE ARE ~$740M+ Global Revenue* Pain Management Chronic Care Diversified portfolio with 8 market-leading products in the U.S. International Business operations in 90+ countries U.S. Creating Shareholder Value ~$10B Addressable Market Optimized cost structure M&A execution and integration Organi
Slide 4: Our Evolution
4 1970s - 2014 2014 2016 2018 2019 2020 • Completed spin-off as Halyard Health • Acquired CORPAK Medsystems • Acquired NeoMed, Summit and endOclear 2021 • Announced intent to acquire OrthogenRx (anticipated close in January 2022) • Launched stock repurchase program • Deliver revenue growth and margi
Slide 5: 2021 in Review
EXECUTION ✓ Strong sales performance – will meet growth guidance metrics (2 – 4%) ✓ Effective OPEX management reduced SG&A; partially offsetting COGS ✓ Efficient capital deployment with M&A and share repurchase ✓ Retired significant legal matters providing additional clarity to 2022 Free Cash Flow ✓
Slide 6: Our Franchises
NN Wo me Our Franchises ,< y~\ AVANOS
Slide 7: Chronic Care
7 CHRONIC CARE Leading market positions enhanced by bolt-on acquisitions Addressable Market Product Portfolio ~$400M Respiratory Health ~$1B Digestive Health Long-term Feeding Nasogastric Feeding Neonatal Feeding Closed Suction Continued market leadership with launch of MIC-KEY* SF in 2020 Demonstra
Slide 8: Pain Management
8 PAIN MANAGEMENT Delivering non-opioid pain relief therapies Addressable Market Product Portfolio >$4B Interventional Pain >$4B Acute Pain 100M >20M Target U.S. surgical procedures Americans in chronic pain ON-Q Summit Medical (2019) Game Ready (2018) Clinically proven non-opioid therapy to reduce
Slide 9: 2022 and Beyond
aN SS a 2022 and Beyond DN y VA Vi,
Slide 10: Well-Positioned to Deliver Sales Growth in Attractive Markets
10 WELL-POSITIONED TO DELIVER SALES GROWTH IN ATTRACTIVE MARKETS GROSS AND OPERATING MARGINS TO IMPROVE THROUGH 2022 FOUR AREAS OF VALUE CREATION ✓ Leverage market-leading positions in Digestive Health, Respiratory Health and Acute Pain leading to 3%-6% organic growth ✓ Maintain double-digit growth
Slide 11: Focus on Capital Deployment
11 FOCUS ON CAPITAL DEPLOYMENT USING STRONG BALANCE SHEET POSITION TO SUPPLEMENT ORGANIC GROWTH IMPROVED MARGINS AND MATERIALLY FEWER ONE-TIME ITEMS WILL GENERATE FREE CASH FLOW ✓ Execute additional bolt-on acquisitions to enhance portfolio ✓ Identify opportunities to optimize portfolio ✓ Complete $
Slide 12: The best at getting patients back to the things that matter
12 The best at getting patients back to the things that matter
Avanos Medical — J.P. Morgan Healthcare Conference 2022 on 6ix